Precigen, Inc., (PGEN) is a global-level biotherapeutics company developing gene and cell therapeutics. The key product line of the company includes UltraCAR-T, UltraVector, AdenoVerse Immunotherapy, and ActoBiotics.
PGEN stock price during the regular trading on March 14, 2022, dipped by 7.28% to be $1.91. Its price rebounded by 10.9% at the last check of the after-market session of March 15, 2022.
PGEN: Key Financials
On March 1, 2022, PGEN released a consolidated Q4 2021 financial statement for three months ended December 31, 2021. Some important highlights are shared here.
Revenue
Total revenue in Q4 2021 was $24.2 million corresponding to $19.3 million in the comparable period in 2020. The company’s revenue soared by $4.9 million over the yearly span. Also, it surpassed the revenue expectations by $1.98 million
EPS
Q4 2021 basic and diluted net loss per share was $25 million or $0.13 compared to $41.6 million or $0.23 in the corresponding period of 2020. The company’s EPS increased year-over-year. Also, it surpassed the EPS estimations by $0.01.
PGEN: Events and Happenings
On January 12, 2022, PGEN reported that its Executive management presented pipeline and corporate features of the company at the 40th Annual J.P. Morgan Healthcare Conference. The conference was held on the same date.
On December 13, 2021, PGEN announced the presentation of optimistic interim data of Phase 1 trials of PRGN-3006 UltraCAR-T at the 63rd Annual Meeting and Exposition of ASH. PRGN-3006 is under clinical trials for the treatment of patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
On November 10, 2021, PGEN updated on the participation of its Executive management at the Virtual Stifel 2021 Healthcare Conference held on November 17, 2021.
Conclusion
PGEN stock declined by up to 50% year-to-date. In the after-market session of Monday, the company’s stock rebounded as a result of uncertainty as no official press release or SEC filing is updated on its official website neither an event is planned immediately. The expected date of the first quarter 2022 financial statement release is May 9 and revenue guidance is in the range of $23.2 million with -$0.13 EPS.
